P
Pelago
Virtual clinic offering personalized substance-use care—covering tobacco, alcohol, opioids, and cannabis—via employer and health plan partnerships
About Pelago
Pelago is a New York–based digital health company offering a virtual clinic focused on personalized substance use management. Originally founded in 2017 as Quit Genius, the company later rebranded to Pelago to broaden its scope beyond smoking cessation and to better reflect its holistic approach to behavioral health care.
Read full description
Pelago operates via a mobile app provided at no cost to individuals through employer or health plan benefits. The service is fully digital, confidential, and available 24/7. Its care model combines telehealth consultations with a multidisciplinary team—including physicians, nurses, counselors, and health coaches—and evidence-based therapies such as cognitive behavioral therapy, remote monitoring devices, and medication-assisted treatment through its PelagoRx program.
At the core of its platform is a tailored continuum of care that addresses substance use across prevention, habit reduction, and disorder treatment. The company’s approach is personalized based on individual health status, behavior patterns, genetic factors, and user-defined goals.
Pelago reports clinically significant outcomes: a reduction in alcohol use of over 60% within one month, long-term tobacco quit rates of 44% at 12 months, and opioid abstinence among nearly two-thirds of participants after 90 days.
For employers and health plans, Pelago offers measurable cost savings and productivity gains. The company estimates medical cost reductions of over $6,000 per participant in the first year, translating to an estimated return on investment of 4.5 to 1.
Founded by a team of physicians and behavioral health specialists, Pelago continues to expand its partnerships with insurers, benefit administrators, and enterprise health programs to provide scalable, stigma-free support for substance use challenges.
At a glance
- Founded
- 2017
- Headquarters
- New York City, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Research & analysis
Latest news
Press, funding announcements and product moves mentioning Pelago.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Y Combinator
Telefonica
Merck & Co.
Force Over Mass Capital
Eric Ries
Arab Angel Fund
Village Global
Series A8 investors entered at this stage
StartUp Health
Octopus Ventures
Burda Principal Investments
Venus Williams
Serena Ventures
Atomico
Kinnevik
Triple Point Ventures
Series B and later5 investors entered at this stage
Elevation Capital
Max Mullen
Ariel Poler
Eight Roads Ventures
Greymatter Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pelago on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pelago on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
